WANY
RCUS icon

Wealthspire Advisors (New York)’s Arcus Biosciences RCUS Stock Holding History

Wealthspire Advisors (New York)’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-126
Closed -$1.71K – 2451
2025
Q3 		$1.71K Buy
+126
New +$1.31K ﹤0.01% 2644

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Wealthspire Advisors (New York)'s RCUS Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 126 shares — an estimated $1.71K sold.

Wealthspire Advisors (New York) first reported a position in RCUS in Q3 2025 and held it in 1 quarter. The position peaked at $1.71K in Q3 2025. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 126 Arcus Biosciences shares in Q4 2025, an estimated $1.71K.
  • Wealthspire Advisors (New York) first reported a position in Arcus Biosciences in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Arcus Biosciences position peaked at $1.71K in Q3 2025.
  • 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.